RxDoctor Payments Data

Punit Jariwala, MD

Internal Medicine · West Long Branch, NJNPI 1386060507

Payments from drug & device makers

$590in general payments, 2019–2025

Across 26 payments — averaging $22.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$256
  • SK Life Science, Inc.$125
  • AbbVie$69
  • Pfizer$39
  • Novartis$30
  • Sunovion Pharmaceuticals Inc.$21
  • plus $51 from 3 others

What the payments were for

  • Food & beverage$590100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$590 in reported general payments places this provider in the 55th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$694,499
Medicare patients
787
Services billed
4,817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban278$74,092
VelphoroSucroferric Oxyhydroxide23$15,350
EntrestoSacubitril/Valsartan32$14,106
TradjentaLinagliptin35$12,388
Breo ElliptaFluticasone/Vilanterol25$10,568
JardianceEmpagliflozin29$9,317
Incruse ElliptaUmeclidinium Bromide26$8,893
JanuviaSitagliptin Phosphate29$7,810
Victoza 2-PakLiraglutide20$5,800
MyrbetriqMirabegron55$5,531
FarxigaDapagliflozin Propanediol11$5,046
LokelmaSodium Zirconium Cyclosilicate21$4,754
XareltoRivaroxaban19$4,672
SantylCollagenase Clostridium Hist.12$4,056
Atorvastatin Calcium281$3,063

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$39$74,092278 claims
NovartisEntresto$30$14,10632 claims
AstraZenecaFarxiga, Lokelma$19$9,80032 claims
Johnson & JohnsonXarelto$256$4,67219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in West Long Branch

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →